UNIVERSAL

Laurus Labs has submitted an application to the US Food and Drug Administration (FDA) for the tentative approval of paediatric Darunavir/ritonavir (pDRV/r (120/20 mg)). UNIVERSAL is the first product development project from the World Health Organisation’s (WHO) GAP-F project which was established to promote the development of safer,

In recent years, advancements in medical research have paved the way for an array of treatment options for children living with HIV. The efforts of scientists and researchers globally, have led to continuous refinement and improvement of existing regimens.

FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. (Nasdaq: GILD) is pleased to announce two public-private partnerships. The first will accelerate the development of an investigational dispersible pediatric formulation containing emtricitabine and tenofovir alafenamide (F/TAF).

The inaugural Clinical Trial Management training program took place online on Wednesday, 14 June 2023, after 428 participants registered. The session was well attended by up to 168 clinical trial staff representing 30 countries. 

[vc_row][vc_column][vc_column_text]By design, capacity building is a fundamental part of the UNIVERSAL project. The aim of the project’s capacity building activities are to improve the ability of African and European young investigators in designing and conducting clinical trials.

A while ago, we sat with Marc Lallemant – the scientific coordinator of the UNIVERSAL project led by Penta, for a quick chat. It was an eye-opening discussion that delved into the early beginnings and the birth of the project.

Penta is the coordinator for the newly funded EDCTP project – UNIVERSAL!  Later in the day, we will be speaking with partners at the official kick-off meeting.